Synthesis, Crystal Structure, Hirshfeld Surface Analysis and Docking Studies of a Novel Flavone–Chalcone Hybrid Compound Demonstrating Anticancer Effects by Generating ROS through Glutathione Depletion

Chalcones and Gastrointestinal Cancers: Experimental Evidence

Colorectal (CRC) and gastric cancers (GC) are the most common digestive tract cancers with a high incidence rate worldwide. The current treatment including surgery, chemotherapy or radiotherapy has several limitations such as drug toxicity, cancer recurrence or drug resistance and thus it is a great challenge to discover an effective and safe therapy for CRC and GC. In the last decade, numerous phytochemicals and their synthetic analogs have attracted attention due to their anticancer effect and low organ toxicity. Chalcones, plant-derived polyphenols, received marked attention due to their biological activities as well as for relatively easy structural manipulation and synthesis of new chalcone derivatives. In this study, we discuss the mechanisms by which chalcones in both in vitro and in vivo conditions suppress cancer cell proliferation or cancer formation.

The crystal structure of (Z)-2-(2,3-dimethoxybenzylidene)naphtho[1,2-b]furan-3(2H)-one, C21H16O4

C21H16O4, monoclinic, P21/n (no. 14), a = 13.531(6) Å, b = 8.390(3) Å, c = 14.288(5) Å, β = 95.322(15)°, V = 1615.1(11) Å3, Z = 4, Rgt (F) = 0.0588, wRref (F 2) = 0.1795, T = 243(2) K.

The crystal structure of 2-(4-methoxynaphthalen-1-yl)-4H-chromen-4-one, C20H14O3

C20H14O3, triclinic, P 1 ‾ $P\overline{1}$ (no. 2), a = 8.3085(10) Å, b = 8.3918(8) Å, c = 12.1359(14) Å, α = 91.691(5)°, β = 107.708(5)°, γ = 113.607(5)°, V = 727.42(14) Å3, Z = 2, R gt (F) = 0.0471, wRref (F 2) = 0.1235, T = 223(2) K.